Ideaya goes forward with $150M offering after touting PhII cancer data
Ideaya Biosciences has lifted the cover on some data for its metastatic uveal melanoma (MUM) treatment while also forging ahead with an offering of its stock.
Over the weekend, Ideaya dropped interim results from its Phase II clinical trial investigating a combination of darovasertib and crizotinib to treat MUM. On top of these data, the biotech is moving ahead with an offering of up to $150 million of shares of its common stock in a public offering.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.